{
    "clinical_study": {
        "@rank": "48626", 
        "acronym": "NoSIRS", 
        "arm_group": [
            {
                "arm_group_label": "Vagal Nerve Stimulation", 
                "arm_group_type": "Experimental", 
                "description": "30 minutes of vagal nerve stimulation using a catheter in the IJV"
            }, 
            {
                "arm_group_label": "Sham stimulation", 
                "arm_group_type": "Sham Comparator", 
                "description": "Catheter placed in the IJV without stimulation"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the effect of transvenous vagus nerve stimulation\n      (tVNS) on the immune response.\n\n      In the human endotoxemia model, intravenously administered endotoxin (lipopolysaccharide\n      [LPS]) elicits a systemic immune response with release of pro-inflammatory cytokines, such\n      as TNF \u03b1. This trial will determine if an anti-inflammatory effect can be produced by acute\n      VNS using a minimally invasive delivery method."
        }, 
        "brief_title": "Effects of Transvenous Vagus Nerve Stimulation on Immune Response: a Pilot Study", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Inflammation", 
        "condition_browse": {
            "mesh_term": "Inflammation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Written informed consent to participate in this trial\n\n          2. Male subjects aged 18 to 35 years inclusive\n\n          3. Healthy as determined by medical history, physical examination, vital signs, 12 lead\n             electrocardiogram, and clinical laboratory parameters\n\n        Exclusion Criteria:\n\n          -  Use of any medication(including herbal remedies and vitamin/mineral supplements) or\n             recreational drugs within 7 days prior to profiling day\n\n          -  Smoking\n\n          -  Use of caffeine, or alcohol or within 1 day prior to profiling day\n\n          -  Previous participation in a trial where LPS was administered\n\n          -  Surgery or trauma with significant blood loss or blood donation within 3 months prior\n             to profiling day\n\n          -  Participation in another clinical trial within 3 months prior to profiling day.\n\n          -  History, signs or symptoms of cardiovascular disease\n\n          -  An implant that in the opinion of the investigator may make invasive procedures risky\n             for the subject due to the increased risks associated with a possible infection.\n\n          -  Subject has an implanted active cardiac device (ICD, IPG and/or CRT)\n\n          -  Implanted active neurostimulation device\n\n          -  Subject has internal jugular vein that cannot be accessed\n\n          -  History of vaso-vagal collapse or of orthostatic hypotension\n\n          -  History of atrial or ventricular arrhythmia\n\n          -  Resting pulse rate \u226445 or \u2265100 beats / min\n\n          -  Hypertension (RR systolic >160 or RR diastolic >90)\n\n          -  Hypotension (RR systolic <100 or RR diastolic <50)\n\n          -  Conduction abnormalities on the ECG consisting of a 1st degree atrioventricular block\n             or a complex bundle branch block\n\n          -  Subject is diagnosed with epilepsy or history of seizures\n\n          -  Renal impairment: plasma creatinine >120 \u00b5mol/L\n\n          -  Liver function abnormality: alkaline phosphatase>230 U/L and/or ALT>90 U/L\n\n          -  Coagulation abnormalities: APTT or PT > 1.5 times the reference range\n\n          -  History of asthma\n\n          -  Immuno-deficiency\n\n          -  CRP > 20 mg/L, WBC > 12x109/L, or clinically significant acute illness, including\n             infections, within 2 weeks before profiling day\n\n          -  Known or suspected of not being able to comply with the trial protocol\n\n          -  Inability to personally provide written informed consent (e.g. for linguistic or\n             mental reasons) and/or take part in the study."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "35 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01944228", 
            "org_study_id": "NoSIRS Study", 
            "secondary_id": "2012-005687-97"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vagal Nerve Stimulation", 
                "description": "30 minutes of vagal nerve stimulation using a catheter in the IJV", 
                "intervention_name": "Vagal Nerve Stimulation", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Sham stimulation", 
                "description": "Catheter placed in the IJV without stimulation", 
                "intervention_name": "Sham Stimulation", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "inflammation", 
            "vagus nerve stimulation", 
            "chronic heart failure", 
            "Systemic Inflammatory Response Syndrome", 
            "sepsis", 
            "auto-immune diseases"
        ], 
        "lastchanged_date": "October 29, 2013", 
        "link": [
            {
                "description": "Prof. P. Pickkers, MD, PhD", 
                "url": "http://www.umcn.nl/Research/Departments/intensive%20care/Pages/Pickkers.aspx"
            }, 
            {
                "description": "Dr. Matthijs Kox", 
                "url": "http://www.umcn.nl/Research/Departments/intensive%20care/Pages/Kox.aspx"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Nijmegen", 
                    "country": "Netherlands", 
                    "zip": "9101"
                }, 
                "name": "Radboud University Nijmegen Medical Centre"
            }
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Transvenous Vagus Nerve Stimulation on Immune Response: a Pilot Study", 
        "overall_official": {
            "affiliation": "Radboud University", 
            "last_name": "Peter Pickkers, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "The Netherlands: Central Committee for Research Involving Human Subjects (CCMO)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Plasma TNF-\u03b1 concentration after LPS administration (Area Under Curve); comparison of subjects treated with tVNS versus sham tVNS.", 
            "measure": "Plasma TNF-\u03b1 concentration", 
            "safety_issue": "No", 
            "time_frame": "24 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01944228"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Plasma concentrations of pro-inflammatory and anti-inflammatory cytokines (including TNF-\u03b1, IL 6, IL 1RA, IL 10) up to 24 h after LPS injection to document the immune response up to 24 hrs; comparison of subjects treated with tVNS versus sham tVNS.", 
                "measure": "Plasma concentrations of pro-inflammatory and anti-inflammatory cytokines", 
                "safety_issue": "No", 
                "time_frame": "up to 24 h"
            }, 
            {
                "description": "Leukocyte responses to ex vivo stimulation with inflammatory stimuli and leukocyte phagocytosis capacity up to 24 hrs; comparison of subjects treated with tVNS versus sham tVNS", 
                "measure": "Leukocyte responses to ex vivo stimulation", 
                "safety_issue": "No", 
                "time_frame": "up to 24 hrs"
            }, 
            {
                "description": "Endotoxemia-related clinical symptoms, hemodynamic parameters, and temperature up to 24 hrs; comparison of subjects treated with tVNS versus sham tVNS.", 
                "measure": "Endotoxemia-related clinical symptoms", 
                "safety_issue": "No", 
                "time_frame": "up to 24 hrs"
            }, 
            {
                "description": "Endotoxemia-induced circulating leukocyte changes up to 24 hrs; comparison of subjects treated with tVNS versus sham tVNS.", 
                "measure": "Endotoxemia-induced circulating leukocyte changes", 
                "safety_issue": "No", 
                "time_frame": "up to 24 hrs"
            }, 
            {
                "description": "Autonomic nervous system activity measured by heart rate variability up to 24 hrs; comparison of subjects treated with tVNS versus sham tVNS.", 
                "measure": "Autonomic nervous system activity", 
                "safety_issue": "No", 
                "time_frame": "up to 24 hrs"
            }, 
            {
                "description": "Tolerability of acute side effects of tVNS.  Subject feedback during VNS.", 
                "measure": "Tolerability of acute side effects of tVNS", 
                "safety_issue": "No", 
                "time_frame": "Acute 30 min stimulation"
            }, 
            {
                "description": "Perception of delivery difficulty.", 
                "measure": "Ease of tVNS delivery", 
                "safety_issue": "No", 
                "time_frame": "acute interoperative"
            }
        ], 
        "source": "Medtronic Cardiac Rhythm Disease Management", 
        "sponsors": {
            "collaborator": {
                "agency": "Radboud University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Medtronic Cardiac Rhythm Disease Management", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}